AGGF-1 Expression as a Predictive Biomarker for Anti-VEGF Therapy in Metastatic Colorectal Cancer
Eurasian Journal of Medical Investigation · 2026 · 54-59
DOI: 10.14744/ejmi.263054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medical Investigation, 2026. Verfasst von Burcu Gülbağcı und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
Metastatic colorectal cancer (mCRC) remains a major therapeutic challenge, and predictive biomarkers for anti-angiogenic therapy are still lacking. Angiogenic factor with G-patch and FHA domain 1 (AGGF-1) is a pro-angiogenic protein that has been associated with unfavorable prognosis in several malignancies. However, its clinical significance in mCRC, particularly in patients receiving bevacizumab-based chemotherapy, has not been clearly defined.
Methods
This retrospective study encompassed 67 patients with mCRC who received first-line bevacizumab-based chemotherapy. Tumor specimens were evaluated for AGGF-1 expression by immunohistochemistry. AGGF-1 expression was assessed based on staining proportion and staining intensity.
Results
AGGF-1 expression was detected in 33 patients (49.3%) and was more frequent in de novo metastatic disease than in recurrent disease (p = 0.026). Patients exhibiting AGGF-1 expression demonstrated numerically reduced overall survival (OS) and progression-free survival (PFS); however, these disparities lacked statistical significance. In multivariate analysis, AGGF-1 staining intensity was independently associated with PFS (p=0.009). Location of the primary tumor predicted both OS and PFS, whereas metastasectomy correlated with enhanced OS.
Conclusion
AGGF-1 expression may be associated with unfavorable outcomes in bevacizumab-treated mCRC. Prospective studies are needed to clarify its prognostic value.
Zitieren
APA
Gülbağcı, B., Çakır, E., Turan, G., Özkul, Ö., & Hacibekiroğlu, I. (2026). AGGF-1 Expression as a Predictive Biomarker for Anti-VEGF Therapy in Metastatic Colorectal Cancer. Eurasian Journal of Medical Investigation, 54-59. https://doi.org/10.14744/ejmi.263054
Vancouver
Gülbağcı B, Çakır E, Turan G, Özkul Ö, Hacibekiroğlu I. AGGF-1 Expression as a Predictive Biomarker for Anti-VEGF Therapy in Metastatic Colorectal Cancer. Eurasian Journal of Medical Investigation. 2026:54-59. doi:10.14744/ejmi.263054
BibTeX
@article{Glbac2026,
author = {Gülbağcı, Burcu and Çakır, Emre and Turan, Gupse and Özkul, Özlem and Hacibekiroğlu, Ilhan},
title = {AGGF-1 Expression as a Predictive Biomarker for Anti-VEGF Therapy in Metastatic Colorectal Cancer},
journal = {Eurasian Journal of Medical Investigation},
year = {2026},
pages = {54--59},
doi = {10.14744/ejmi.263054}
}
EUVIMED